AI Article Synopsis
- The study assessed the clinical implications of pancreatic steatosis, or fat accumulation in the pancreas, using endoscopic ultrasonography (EUS) amid rising metabolic syndrome concerns.
- It involved 243 patients divided into four groups, analyzing the relationship between the echogenicity (brightness on imaging) of the pancreas versus control organs, determining key cut-off ratios.
- Findings indicated significant correlations between factors like sex, alcohol use, and fatty pancreas, highlighting that ectopic fat in the pancreas may signal serious conditions such as pancreatic cancer, particularly in high-risk individuals.
Article Abstract
Background: Taking advantage of the current advances in diagnostic imaging modalities, including endoscopic ultrasonography (EUS), and due to the increased attention to ectopic fat accumulation in the pancreas following the rising trend of metabolic syndrome, we qualitatively assessed the clinical implication of pancreatic steatosis by EUS in this study.
Methods: The study included 243 patients that were divided into four groups. The correlation between the average echogenicity of the pancreas and that of the control organs and the key clinical data of all study patients were collectively analyzed. The cut-off point of the pancreas-control (PC) ratio in EUS and liver-control (LC) ratio on abdominal ultrasound were determined from the population distribution and the obtained median values.
Results: With the cut-off point of 1.30 for the PC ratio and 1.20 for the LC ratio, sex, the Brinkman index, habitual alcohol drinkers, and fatty pancreas were significant factors. The associations between each relevant factor in fatty pancreas, metabolic syndrome in the fatty liver group, and age in the pancreatic cancer group were all significant in the analysis. In addition, we investigated whether the PC ratio differed according to age and staging in pancreatic cancer patients. Interestingly, the PC ratio was lower in the advanced stage group than in the early-stage group.
Conclusion: Our results suggest that, irrespective of the degree, ectopic fat infiltration in the pancreas could be a specific clinical phenotype of serious pancreatic diseases, including pancreatic cancer, especially in high-risk patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762627 | PMC |
| http://dx.doi.org/10.1002/jgh3.12692 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Semaglutide alleviates the pancreatic β cell function via the METTL14 signaling and modulating gut microbiota in type 2 diabetes mellitus mice.
Life Sci
January 2025
Department of Endocrinology and Metabolism of the Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang City, Jiangxi Province, China; Institute for the Study of Endocrinology and Metabolism in Jiangxi Province, Nanchang City, Jiangxi Province, China; Branch of National Clinical Research Center for Metabolic Diseases, Nanchang City, Jiangxi Province, China. Electronic address:
Aims: Semaglutide, a novel long-acting GLP-1RA, stimulates insulin and suppresses islet-secreted glucagon to reduce glucose levels. It has been unveiled that m6A mRNA modification plays a pivotal role in regulating β cell function. However, it remains unclear whether semaglutide can elicit protective effects through manipulating m6A modification and the underlying mechanism.
View Article and Find Full Text PDFHigh prevalence of pancreatic steatosis in pancreatic cancer patients: A meta-analysis and systematic review.
Pancreatology
November 2024
Department of Gastroenterology, HagaZiekenhuis Hospital, The Hague, Netherlands. Electronic address:
Objective: In the last decade there has been increasing interest in defining pancreatic steatosis (PS) and establishing its association with pancreatic ductal adenocarcinoma (PDAC). However, no consensus guidelines have yet been published on the management of PS. In this systematic review and meta-analysis performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we investigated the association between PS and PDAC.
View Article and Find Full Text PDFBeta-cell, but not autonomic nervous system, function is related to MAFLD in early stages of glucose intolerance.
BMJ Open Diabetes Res Care
December 2024
Department of Endocrinology, Medical University-Sofia, Sofia, Bulgaria.
Introduction: Previous studies have suggested an association between beta-cell and autonomic function and metabolic-associated fatty liver disease (MAFLD). We explored the association between controlled attenuated parameter (CAP) and insulin secretion and action, as well as sympathetic and parasympathetic activity in normal (NGT) and impaired (IGT) glucose tolerance.
Research Design And Methods: Twenty-five NGT (age 44.
A comprehensive atlas of multi-tissue metabolome and microbiome shifts: Exploring obesity and insulin resistance induced by perinatal bisphenol S exposure in high-fat diet-fed offspring.
J Hazard Mater
December 2024
College of Ocean Food and Biological Engineering, Jimei University, Xiamen 361021, China; Research Unit Analytical BioGeoChemistry, Helmholtz Munich, Neuherberg 85764, Germany; Xiamen Key Laboratory of Marine Functional Food, Xiamen 361021, China. Electronic address:
Bisphenol S (BPS) is widely used as a substitute for Bisphenol A (BPA). While perinatal BPS exposure is suspected to increase susceptibility to high-caloric diet-induced adipogenesis, how BPS affects offspring remains largely unknown. This study explored effects of prenatal BPS exposure on adiposity and insulin resistance in high-fat diet (HFD)-fed C57BL/6 offspring, revealing significant changes in body weight, glucose tolerance, insulin sensitivity, and histopathology.
View Article and Find Full Text PDFSGLT2 inhibition and adipose tissue metabolism: current outlook and perspectives.
Cardiovasc Diabetol
December 2024
Centro Malattie Endocrine e Metaboliche, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have emerged as important agents for the treatment of type 2 diabetes mellitus (T2DM). SGLT2 inhibitors have been associated with improved cardiovascular outcomes, not only through their immediate hemodynamic effects-such as glycosuria and (at least temporary) increased natriuresis-but also due to their multifaceted impact on metabolism. Recently, studies have also focused on the effects of SGLT2 inhibitors on adipose tissue.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!